Background: Ranitidine was the most prescribed histamine-2 receptor antagonist (H2RA) in
Canada when recalled in 2019 because of potential carcinogenicity. We sought to compare …

Importance Ranitidine, the most widely used histamine-2 receptor antagonist (H 2 RA), was
withdrawn because of N-nitrosodimethylamine impurity in 2020. Given the worldwide …

Ranitidine Use and Cancer Risk: Results From UK Biobank - Gastroenterology Skip to Main
Content Advertisement Gastroenterology American Gastroenterological Association Home …

Introduction Ranitidine, a histamine H2-receptor antagonist (H2RA), is indicated in the
management of gastric acid-related disorders. In 2020, the European Medicines Agency …

Abstract Introduction In September 2019, ranitidine and nizatidine were suggested to
contain N-nitrosodimethylamine, a carcinogenic substance. People have since been …

Background: The discovery that ranitidine is contaminated with N-nitrosodimethylamine, a
suspected human carcinogen, raises the hypothesis of a gastrointestinal carcinogenic effect; …

Simple Summary There is a lack of published data regarding the association between N-
nitrosodimethylamine and human cancer risks. Hence, this study answers several questions …

We thank Dr. Karp for his interest in our study (1) and agree of course that randomized
controlled trials (RCT) are the ideal approach to eliminate confounding at baseline. But …

Objective: On September 2019, the United States Food and Drug Administration announced
that some ranitidine products were contaminated with unacceptable levels of N …

Background: In 2019, ranitidine was withdrawn due to high levels of N-
nitrosodimethylamine, a probable human carcinogen. The risk of bladder and kidney cancer …